Where Biologic Stability Programs Fail — And How ICH Q1 Can Help You Get It Right

For decades, biologics stability programs followed a predictable playbook: generate data, support regulatory filings, satisfy agencies, and move on. That model is changing. With the release of the draft International Council for Harmonisation (ICH) Q1 guidance, stability is shifting from a back-end regulatory exercise to a front-line development and risk-management discipline. Programs that once progressed quietly are now being scrutinized more closely, and assumptions that previously seemed acceptable may now represent regulatory or operational risk. Teams that fail to adapt early often discover problems late — during IND preparation, comparability assessments, regulatory review, or commercial scale-up — when corrective actions are costly and highly visible.

The draft ICH Q1 guidance represents a significant shift in how stability programs for biologics, vaccines, and advanced modalities must be designed, executed, and justified across the product lifecycle. Greater emphasis is now placed on real-world storage conditions, analytical rigor, forced degradation and excursion studies, and proactive lifecycle management.

This session examines how these evolving expectations are reshaping stability strategy and why traditional approaches often fall short. Drawing on real-world case studies from biologics development and GMP programs, it highlights common late-stage risks — including shipment-induced degradation, solvent loss in semi-permeable containers, container–closure compatibility failures, misleading potency or impurity trends, and comparability challenges — and discusses how a stronger stability design can support confident IND, BLA, and long-term supply strategies.